Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T16:43:18.443Z.
Calculation as of: 2026-10-06T16:43:18.443Z.
Quote observation: 2026-10-06T16:40:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e0aae41c25609cbe98cd8c59fbdc20e812e1ea61d6a67e0b8df2c56749153647
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Kyverna Therapeutics, Inc.
Market Cap
$383.90M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$381.24M
Price/OCF Ratio
N/A
TTM Avg
21.33
3Y Avg
20.74
5Y Avg
20.74
Market Cap
$386.60M
Price/OCF Ratio
22.68
TTM Avg
17.52
3Y Avg
18.34
5Y Avg
28.47
Market Cap
$397.20M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$359.09M
Price/OCF Ratio
N/A
TTM Avg
46.02
3Y Avg
35.66
5Y Avg
31.75
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | $383.90M | N/A | N/A | N/A | N/A |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $381.24M | N/A | 21.33 | 20.74 | 20.74 |
| Orthofix Medical Inc. (OFIX)vs › | $386.60M | 22.68 | 17.52 | 18.34 | 28.47 |
| REGENXBIO Inc. (RGNX)vs › | $390.83M | N/A | 6.23 | 6.23 | 34.97 |
| Canopy Growth Corporation (CGC)vs › | $374.11M | N/A | N/A | N/A | N/A |
| MapLight Therapeutics, Inc. (MPLT)vs › | $397.20M | N/A | N/A | N/A | N/A |
| Opus Genetics, Inc. (IRD)vs › | $363.70M | N/A | N/A | N/A | N/A |
| Carlsmed, Inc. (CARL)vs › | $404.51M | N/A | N/A | N/A | N/A |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $359.09M | N/A | 46.02 | 35.66 | 31.75 |
| Embecta Corp. (EMBC)vs › | $359.28M | 2.06 | 2.73 | 12.47 | 9.98 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
